Disease-Modifying Therapy

BARCELONA, Spain — September 10, 2026 CONNECTA Therapeutics announced the closing of a €3.1 million financing led by new...

San Mateo, California, USA, September 3, 2026 Kali Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...

Tokyo, Japan and Cambridge, Massachusetts, USA, September 3, 2026 Eisai Co., Ltd. and Biogen Inc. announced that China’s National...

ATHENS, Greece, September 1, 2026 Stoke Therapeutics and Biogen announced presentations of clinical data supporting the potential of zorevunersen,...

TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...

Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...

Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...